Award Number: **W81XWH-12-1-0331**

TITLE: Apoptosis Induction by Targeting Interferon Gamma Receptor 2 (IFNgammaR2) in Prostate Cancer: Ligand (IFNgamma)-Independent Novel Function of IFNgammaR2 as a Bax Inhibitor

PRINCIPAL INVESTIGATOR: Shigemi Matsuyama

CONTRACTING ORGANIZATION: Case Western Reserve University
Cleveland, OH 44106-1712

REPORT DATE: August 2014

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE August 2014		2. REPORT TYPE Annual		3. DATES COVERED 1August2013-31July2014	
4. TITLE AND SUBTITLE Apoptosis Induction by Targeting Interferon Gamma Receptor 2 (IFNgammaR2) in Prostate Cancer: Ligand (IFNγ)-independent novel function of IFNγR2 as a Bax inhibitor				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-12-1-0331	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Shigemi Matsuyama Email: shigemi.matsuyama@case.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Case Western Reserve University Cleveland, OH 44106-1712				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT In our preliminary study, we found that IFNγR2 has previously unknown function as an inhibitor of Bax. Bax is a key mediator of apoptosis. We found that IFNγR2 is overexpressed in prostate cancer, and we hypothesize that abnormally high level of IFNγR2 confers apoptosis resistance of prostate cancer. In this project, we will investigate the role of IFNγR2 in drug resistance of prostate cancer and explore the development of therapeutic peptide that can activate Bax-induced apoptosis in prostate cancer by inactivating IFNγR2. In Year 2, we planned to determine the presence of subtype of prostate cancer expressing high levels of IFNγR2 and Bax which is expected to be an ideal target subtype treated by IFNγR2 inhibiting strategy. We also planned to determine the effectiveness of IFNγR2 inhibition both in mouse model and cell culture model. We obtained results showing that (1) majority of prostate cancer tissue showed increased expression of IFNγR2 in comparison with normal prostate tissue, and that (2) IFNγR2 knockdown suppressed tumor growth (human cancer cells were transplanted to mouse) in nude mouse, and (3) parthenolide, a plant-derived compound, was able to decrease IFNγR2 expression in prostate cancer cells and induced cell death. We will continue our investigation to determine the mechanism of IFNγR2 over-expression in prostate cancer, and to develop technologies to induce prostate cancer cell death by targeting IFNγR2.					
15. SUBJECT TERMS- none provided					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES F€	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	10
Reportable Outcomes.....	10
Conclusion.....	n/a
References.....	n/a
Appendices.....	n/a

Introduction

In our preliminary study, we identified interferon γ receptor 2 (IFN γ R2) as a Bax suppressor using yeast-based functional screening of Bax inhibiting proteins. Bax is a key mediator of apoptosis which is essential for chemotherapy-induced apoptosis of prostate cancer cells. We found that IFN γ R2 levels is abnormally elevated in prostate cancer cell lines (both androgen-dependent and – independent cell lines). shRNA-mediated knockdown of IFN γ R2 was able to increase chemotherapy-induced apoptosis rate significantly in prostate cancer cells, suggesting that IFN γ R2 is an chemo-resistant factor in prostate cancer cells. Although IFN γ R2 was previously known as a receptor of IFN γ which is an anti-tumorigenic cytokine, our preliminary data suggest that IFN γ R2 expresses its anti-apoptosis (anti-Bax) activity independent from IFN γ and IFN γ signaling. Importantly, we found that IFN γ R2 is expressed in mitochondrial membranes and ER membranes, but not on the plasma membranes of prostate cancer cells. Since we found that IFN γ R2 can directly interact with Bax in vitro, we hypothesize that IFN γ R2 confer apoptosis resistance of prostate cancer by directly binding and inhibiting Bax.

In this 3 years DOD Prostate Cancer Research IDEA project, the following Tasks will be examined to develop novel anti-prostate cancer therapy as well as to establish IFN γ R2 as a diagnostic maker to predict the chemo-resistance of prostate cancer.

Task 1: To determine the mechanism of Bax inhibition by IFN γ R2, and to develop anti-IFN γ R2 peptide that enhances Bax activation. (Months 1-24)

Task 2: To identify the subtype of prostate cancer that can be effectively treated by IFN γ R2-targeting technologies (Months 13-36)

Task 3: Determination of the mechanism of abnormal expression of IFN γ R2 in prostate cancer (Months 13-36)

I the first year, Task 1 was the main part of our study and we were able to obtain information about the binding domains of IFN γ R2 and Bax, as reported in the last progress report. In Year 2, experiments of Task 2 and Task 3 have started, and we obtain important results that will help us to develop new anti-prostate cancer strategy based on novel anti-apoptotic activity of IFN γ R2. We are also continuing the Task 1 to identify minimum essential binding domain to develop peptide that can inhibit IFN γ R2 activity to suppress Bax-mediated apoptosis.

Body (Methods, Results and Discussion)

Results and Discussion

Task 2: To identify the subtype of prostate cancer that can be effectively treated by IFN γ R2-targeting technologies

(1) Tissue Microarray experiments were performed.

We plan to perform two different approaches to investigate IFN γ R2 expression patterns in prostate cancer. One is to examine the correlation between IFN γ R2 expression (and other anti-apoptotic proteins as well as previously known factors influencing prostate cancer behavior such as androgen receptor, Akt, or PTEN, for example) and clinical outcome using patient specimen library, and another one is to utilize commercially available tissue microarray of human prostate cancer. For the first approach, we need to obtain IRB protocol approval. As explained in section (3), we received

Fig.1 Increased expression of INFγR2 was observed in human prostate cancer tissue microarray. (Please see the definition of cancer progression grade (Grade) and metastasis activity (TNM) in the last page of the proposal)

No.	Position	Age	Grade	TNM	INFγR2	Bax	Bcl-2
1	A1	69	2	T2N0M0	++	+	-
2	A2	69	2	T2N0M0	±	+	-
3	A3	76	2-3	T3N1M1b	±~++	+	+
4	A4	76	2-3	T3N1M1b	++	+	±
5	A5	69	2	T2N0M0	+	-	-
6	A6	69	2	T2N0M0	+	-	-
7	A7	76	2-3	T3N1M1b	±and++	-	-
8	A8	76	2-3	T3N1M1b	+	±	-and+
9	B1	72	3-4	T3N0M0	+	+	+(N)
10	B2	72	3-4	T3N0M0	+~±	+	+(N)
11	B3	60	4	T2N0M0	- ~±	+	+and-
12	B4	60	4	T2N0M0	±	±	+and-
13	B7	60	4	T2N0M0	±~+	-	+
14	B8	60	4	T2N0M0	±	±	-
15	B5	72	hyperplasia	T3N0M0	±~++	-and+	±
16	B6	72	hyperplasia	T3N0M0	++	-and+	+
17	C1	43	Normal	-	-	-	-
18	C2	43	Normal	-	-	-	-
19	C3	28	Normal	-	-	±	±
20	C4	28	Normal	-	±	±	±
21	C5	43	Normal	-	-	-	-
22	C6	43	Normal	-	-	-	-
23	C7	28	Normal	-	-~±	-	±
24	C8	28	Normal	-	-~±	±	-

approval, and we will perform this experiment in year 3. In year 2, we examined the second strategy and examined 11 prostate cancer patient samples together with 8 normal prostate specimen as controls. The summary is presented in **Fig.1**.

We found that majority of progressed prostate cancer specimen showed elevated expression of INFγR2, and these cells also express Bax. Some of advanced prostate cancer (such as No. 1-4, 9, 10 and 11 Fig.1) expresses high levels of INFγ2 as well as Bax, but no detectable Bcl-2. In this type, prostate cancer cells may suppress Bax-induced apoptosis mainly by depending on INFγ2, and thus INFγR2 targeting therapy is expected to work well. In the case of prostate cancer expressing both INFγR2 and Bcl2, combinational treatment of INFγR2 inhibitor and Bcl2 inhibitor (such as ABT-263 derivatives) may be effective. We will continue characterization of prostate cancer type by examining expression patterns of INFγR2 and Bcl-2 family member proteins to characterize subtypes of prostate cancer that can be effective targets of INFγR2-inhibiting therapy.

(2) INFγR2 expression patterns in prostate cancer were investigated by analyzing human patient database.

Using Oncomine database (publically available gene expression profile database of human cancer patients), we found that INFγR2 expression levels of prostate cancer are significantly higher than normal prostate as we expected. To determine the significance of INFγR2 elevation in apoptosis-resistance of prostate cancer, we also checked the expression levels of other well-known apoptosis inhibiting proteins such as Bcl-2, Bcl-XL, and Mcl-1. Results are presented in **Fig.2**. Very

interestingly, only IFN γ R2 (3.69 times increase, $p < 0.000115$) and Mcl-1 (3.24 times increase, $p < 0.000319$) showed significant increased expression in prostate cancer in comparison with normal prostate, but not Bcl-2 and Bcl-XL (BCLL1 in the figure). Expression of apoptosis inducer such as Bax and Bak did not show remarkable changes. These results suggest that IFN γ R2 and Mcl1, but not Bcl-2 and BclXL, are the ideal targets to induce Bax/Bak-mediated apoptosis in prostate cancer. This information also suggests that Mcl1 inhibition may be also necessary to induce prostate cancer cell death when IFN γ R2 inhibition is used to enhance Bax-induced apoptosis.

Fig.2 IFN γ R2 expression is higher in prostate cancer than that in normal prostate

(3) IRB protocol has been approved.

In year 3, we are planning to further investigate the correlation of IFN γ R2 expression pattern (levels and subcellular localization) and clinical outcome (survival rate/recurrence rate) using specimens and clinical treatment records in our cancer center (Case Comprehensive Cancer Center). We have already obtained IRB protocol approval for this study.

Task 3: Determination of the mechanism of abnormal expression of IFN γ R2 in prostate cancer (Months 13-36)

(1) Effectiveness of IFN γ R2 inhibition to promote prostate cancer cell death was examined using mouse xenograph experiments.

Fig.3 IFN γ R2 shRNA suppressed tumor growth and promoted cisplatin effects
(Each line represents each mouse treated with cancer cell and drug (or PBS))

We prepared two cancer cell lines in which IFN γ R2 was knocked down by shRNA. These cell lines are PC3 (human prostate cancer cell line) and A375 (human melanoma cell line). We examined A375 cell line, since we found that this cell line also express high levels of IFN γ R2 and this cell line can be used as a model cancer cell line to determine the effectiveness of anti-IFN γ R2 therapy.

We injected one million cells of cancer cells to each nude mouse, and docetaxel (1mg/kg) and cisplatin (5mg/kg) were treated every week to mice. In PC3 cell line experiments, more than a half of docetaxel-treated mice (2-3 out of 4 mice) were dead within two weeks of treatment, therefore we were not able to obtain reportable result. We are planning to repeat this experiments using lower dose of docetaxel. In the case of cisplatin-treated A375 experiments, we were able to obtain preliminary results to determine the effects of IFN γ R2 knockdown. IFN γ R2 knockdown was able to slow down the growth of tumor (Fig.3 panel B) in comparison with control shRNA expressing cells (Fig.3 panel A). Tumor growth after cisplatin-treatment was also suppressed by shRNA-mediated IFN γ R2 knockdown (Fig.3 panel D) in comparison with control (Fig.3 panel C), though whether cisplatin-induced cell death was “enhanced” is not yet clear, since IFN γ R2 shRNA alone (without cisplatin) showed significant suppression of tumor growth (Fig.3 panel A vs B). Further experiments will be performed to determine whether IFN γ R2 knockdown can enhance chemotherapy-induced cell death in prostate cancer.

(2) Effects of NF κ B inhibitor (Parthenolide) to suppress IFN γ R2 expression

To develop technologies targeting IFN γ R2, we proposed to determine the effectiveness of currently available drugs that is predicted to decrease IFN γ R2 expression in prostate cancer. Since previous studies have shown that NF κ B is one of transcription factors that stimulate IFN γ R2 gene expression, we proposed to determine the effects of NF κ B inhibitor. Parthenolide is a plant-derived compound which is known to inhibit NF κ B activity. In our preliminary study, we found that parthenolide was able to decrease IFN γ R2 expression in PC3 prostate cancer cells. In this study, we examined another standard prostate cancer cells, LNCaP cell line (Fig.4). We found that IFN γ R2 expression was suppressed by parthenolide (from 5 μ M) within 1 day after the treatment (Fig. 4 shows the result of 1 day treatment). Importantly, Bax expression was not decreased by this treatment, suggesting that parthenolide can stimulate Bax-mediated cell death by decreasing Bax inhibitor, i.e. IFN γ R2. In our preliminary study, we confirmed that parthenolide, in fact, induces apoptosis in both PC3 and LNCaP cell lines. In year 3, we will examine whether parthenolide can enhance apoptosis triggered by other anti-cancer drugs.

Fig.4 Parthenolide treatment decreased IFN γ R2 expression without changes in Bax expression

Methods:

Immunohistochemistry of human prostate cancer tissue microarray.

Human prostate cancer tissue microarray was purchased from BioMax (Maryland, USA). Immunohistochemistry of IFN γ R2, Bax, and Bcl-2 were performed by the standard methods explained in detail in Abcam website (<http://www.abcam.com/index.html?pageconfig=resource&rid=13046>).

Antibodies used in these experiments are: IFN γ R2 (Abcam, #ab77246), Bax (BD Pharmingen #554104), and Bcl-2 (BD Pharmingen #514202).

Definition of tumor grade in Fig. 1

The Grade 1-3 in Pathology Diagnosis is equivalent to well-differentiated, moderately-differentiated or poorly differentiated, respectively, under microscope.

Grade 1 or well-differentiated: Cells appear normal and are not growing rapidly.

Grade2 or moderately-differentiated: Cells appear slightly different than normal.

Grade3 or poorly differentiated: Cells appear abnormal and tend to grow and spread more aggressively.

Grade 4 or undifferentiated: *(for certain tumors), features are not significantly distinguishing to make it look any different from undifferentiated cancers which occur in other organs.

TNM grading:

T - Primary tumor

Tx - Primary tumor cannot be assessed

T0 - No evidence of primary tumor

Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria

T1 - Tumor invades submucosa

T2 - Tumor invades muscularis propria

T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues

T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum

N - Regional lymph nodes

Nx - Regional lymph nodes cannot be assessed

N0 - No Regional lymph node metastasis

N1 - Metastasis in 1 to 3 regional lymph nodes

N2 - Metastasis in 4 or more regional lymph nodes

M - Distant Metastasis

Mx - Distant metastasis cannot be assessed

M0 - No distant metastasis

M1 - Distant metastasis

Cell culture and cell lysate preparation for Western blot

PC3 and LNCaP cells were obtained from ATCC, and these cells were cultured in DMEM containing 10%FCS and 1% penicillin/streptomycin. To determine the effects of parthenolide, cells were cultured in the presence of various concentration of parthenolide (5, 10, or 20 μ g/ml) for 1 day. Cell lysates were prepared by solubilizing cell pellets using 1% NP40 containing HEPES buffer. Insoluble fraction was removed by centrifuge separation (14k rpm for 20n min at 4C). For the analysis of protein expression, cell lysates containing 10 μ g protein were used. SDS-PAGE was performed by using 4-20% gradient gel, and immuno-detection was performed by ECA Chemical luminescence detection kit (Amersham).

Mouse xenograph experiments

One million cells of cancer cells (PC3 and A375) were subcutaneously injected to nude mice. One week later, docetaxel (1 mg/kg) or cisplatin (5 mg/kg) were administered (i.p. injection) once a week,

for 4-5 weeks. When tumor size reaches 10% of mouse body, experiments were stopped, and mice were euthanized for tumor size analysis.

Key Research Accomplishment

1. Existence of subtypes of prostate cancer expressing high levels of IFN γ R2 was confirmed by using human prostate cancer tissue micro array and publically available gene expression data base.
2. IRB protocol to determine the correlation between IFN γ R2 expression levels and clinical outcome has been approved.
3. Effectiveness of IFN γ R2 inhibition to enhance anti-cancer drug effects was confirmed by mouse xenograph experiments.
4. Effect of plant-derived NF κ B inhibitor, parthenolide, to decrease expression levels of IFN γ R2 in prostate cancer was found.

Reportable Outcome

We will present this study in the international meeting of interferon held in Melbourne, Australia, in November, 2014. Actually, PI was invited as a selected speaker in this meeting. All the key research accomplishments are reportable results for the future publication. To publish our findings, we think that further study identifying the minimum element for the binding is necessary. We will continue our investigation to prepare manuscript for submission.